The study aims to further improve treatment outcomes by examining whether genotype 2 and 3 patients who do not have a rapid virological response at 4 weeks should have treatment with Pegasys and Copegus
extended to 48 weeks.
can increase the toxicity of certain drugs used to treat HIV.
In addition, Copegus
was priced at a 43 percent discount to its Schering-Plough rival.
The programme is said to be tailored for those patients taking Janssen's hep C pill Incivo (telaprevir) with Roche's injectable interferon treatments Pegasys and Copegus
The partnership will also initially focus on seven medications dispensed through CVS Caremark's specialty pharmacy business: Pegasys and Copegus
for treatment of hepatitis C; as well as oncology drugs Glsevec, Tasigna, SpryceI, Tarceva and Tykerb.
Albuterol * Airet, Proventil, Ventolin, Volmax Ipratropium * Apo-Ipravent, Atrovent, Kendral-Ipratropium Racemic epinephrine * micoNephrine,Vaponefrin Ribavirin * Copegus
, Rebetol, Virazole
The safety profile was typical for Pegasys and Copegus
in populations with abnormal ALT levels, Dr.
Recommended Dosage: 180 [micro]g of Pegasys administered subcutaneously once a week, and (depending on HCV genotype) 800-1,200 mg of Copegus
by mouth daily, for 24 or 48 weeks.
Hoffmann-La Roche for its own version of ribavirin, Copegus
The first study is designed to provide clinical data on the use of VICTRELIS (boceprevir), an oral HCV NS3/4A protease inhibitor, in combination with mericitabine (RO5024048), Roche's investigational oral HCV NS5B nucleoside polymerase inhibitor, Pegasys (pegylated interferon alfa-2a) and Copegus
(ribavirin), in adult patients with chronic HCV genotype 1 infection who had a null response to prior peginterferon alfa and ribavirin therapy (less than a 2 log HCV-RNA decline at treatment week 12).
In addition, the partnership will initially focus on seven medications dispensed through CVS Caremark's specialty pharmacy business, including Pegasys and Copegus
, for the treatment of hepatitis C, as well as the oncology drugs Gleevec, Tasigna, Sprycel, Tarceva and Tykerb.
has not been directly compared with Schering-Plough's combination of Peg-Intron (pegintefferon alfa-2b) and Rebetol, approved in 2001 to treat HCV in interferon-a-naive adults with compensated liver disease.
ILLUMINATE was an open-label, randomised Phase III study that evaluated INCIVEK in combination with Pegasys (pegylated-interferon alfa-2a) and Copegus
(ribavirin) in 540 people with genotype 1 chronic hepatitis C.
Ribavirin Tablets, 500 Zydus Pharmaceuticals Copegus